Evidence map›Paper›PMID 40231502›Full record

ReviewCurrent gene therapy2026

Transforming RNA-Based Gene Therapy with Innovative Nanocarriers for siRNA and miRNA Delivery.

Jitendra Singh Chaudhary, Dilip Kumar Chanchal, Kuldeep Singh, Jeetendra Kumar Gupta, Divya Jain, Anubhav Dubey, Mahima Pandey, Shahbaz Khan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jitendra Singh ChaudharySmt. Vidyawati College of Pharmacy, Jhansi-284128, Uttar Pradesh, India.ORCID 0009-0003-1160-669X
Dilip Kumar ChanchalCollege of Pharmacy, SR Group of Institutions, Ambabai, Jhansi-284419, Uttar Pradesh, India.ORCID 0000-0002-8937-3748
Kuldeep SinghDepartment of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.ORCID 0000-0001-8772-8157
Jeetendra Kumar GuptaDepartment of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.ORCID 0000-0002-5819-371X
Divya JainDepartment of Microbiology, School of Applied and Life Sciences, Uttaranchal University, Dehradun-248007, Uttarakhand, India.ORCID 0000-0001-7220-5687
Anubhav DubeyDepartment of Pharmacology, Maharana Pratap College of Pharmacy, Kanpur, Uttar Pradesh, India.ORCID 0000-0002-9089-4794
Mahima PandeyCollege of Pharmacy, SR Group of Institutions, Ambabai, Jhansi-284419, Uttar Pradesh, India.ORCID 0009-0005-2511-3030
Shahbaz KhanSR College of Pharmaceutical Sciences, Ambabai, Jhansi-284419, Uttar Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cells have been given precise instructions proprio to the regulation of gene expression by the main genesis of Ryan-based gene therapy, which has revived cancer treatment and other disorders. The difficulty of delivering small interfering RNA (siRNA) and microRNA (miRNA) to a target cell is an enormous task and is often faced by researchers due to characteristic instabilities of these carriers and their poor uptake by the cell membrane. The new developments from nanocarrier technologies offer opportunities for better effectiveness of RNA therapy for its delivery and the effectiveness of the treatment regimen. The objective of this article is to provide an overview of the existing as well as the newest developments in nanocarrier technology, particularly as related to microRNA and small interfering RNA (siRNA) delivery. Their modes of operation and their uses in gene therapies are also examined as principles of their design. We focus on several nanocarrier technologies, which have shown proof of concept in multiple disciplines such as stability, controlled release profiles, and delivery. Lipid-based nanoparticles, polymeric systems, and hybrid nanocarriers are some of the platforms that fall under this category; however, this list is not exhaustive. We also study the idea that certain nanocarriers could have multiple functionalities, which would make it possible to improve cancer treatment by simultaneously carrying chemotherapy and genes. We aim to shed light on the future of RNA-based gene therapy by providing a thorough overview of recent research in the field. This will help us understand how novel nanocarrier technologies can tackle the delivery issues.

Indexed as

Genetic TherapyGene Transfer TechniquesMicroRNAsNanoparticlesNeoplasmsRNA, Small InterferingAnimalsDrug CarriersHumansDrug CarriersMicroRNAsRNA, Small InterferingmiRNA deliverynanocarriersnanotechnologyRNA-based gene therapysiRNA deliverytargeted drug delivery

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.